Skip to main content

Advertisement

SpringerLink
Log in

Teplizumab: type 1 diabetes mellitus preventable?

  • Review
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Type 1 diabetes mellitus (T1DM) is an autoimmune condition driven by T lymphocytes that specifically declines the function of beta cells of pancreas. Immunological treatments aim to stop this decline in β-cell function thus preventing TIDM. Although TIDM occur at any age, it is one of the most common chronic disorders in children. T1DM accounts for 5 to 10% of all cases of diabetes amounting 21–42 million affected persons. Teplizumab is a novel drug recently approved by the US FDA for the treatment of T1DM. This drug reduces abnormal glucose tolerance who are at high risk for developing T1DM and have antibodies suggesting an immunological attack on their pancreas. A 14-day infusion of the drug prevents T cells’ attack of the insulin-producing cells of the pancreas. Adverse events due to teplizumab reported so far mild and of limited duration. This review gives an overview of the preclinical and clinical research on teplizumab for their role in new-onset T1DM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Availability of data and materials

Not applicable.

References

  1. Saxby N, Beggs S, Kariyawasam N, Battersby M, Lawn S (2020) Do guidelines provide evidence-based guidance to health professionals on promoting developmentally appropriate chronic condition self-management in children? A Syst Rev Chronic Illn 16(4):239–252

    Article  PubMed  Google Scholar 

  2. Yue Y, Tang Y, Tang J, Shi J, Zhu T, Huang J et al (2018) Maternal infection during pregnancy and type 1 diabetes mellitus in offspring: a systematic review and meta-analysis. Epidemiol Infect 146(16):2131–2138

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Lucier J, Weinstock RS (2022) Diabetes Mellitus Type 1. [Updated 2022 May 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507713/

  4. Zimmet P, Alberti KG, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414(6865):782–787

    Article  CAS  PubMed  Google Scholar 

  5. Chen L, Magliano DJ, Zimmet PZ (2011) The worldwide epidemiology of type 2 diabetes mellitus–present and future perspectives. Nat Rev Endocrinol 8(4):228–236

    Article  PubMed  Google Scholar 

  6. Greenbaum CJ, Speake C, Krischer J, Buckner J, Gottlieb PA, Schatz DA et al (2018) Strength in numbers: opportunities for enhancing the development of effective treatments for type 1 diabetes-the TrialNet experience. Diabetes 67:1216–1225

    Article  PubMed  PubMed Central  Google Scholar 

  7. Atkinson MA, Eisenbarth GS, Michels AW (2014) Type 1 diabetes. Lancet 383(9911):69–82

    Article  PubMed  Google Scholar 

  8. Patterson CC, Gyürüs E, Rosenbauer J, Cinek O, Neu A, Schober E et al (2012) Trends in childhood type 1 diabetes incidence in Europe during 1989–2008: evidence of non-uniformity over time in rates of increase. Diabetologia 55(8):2142–2147

    Article  CAS  PubMed  Google Scholar 

  9. Indian Council of Medical Research (ICMR) [home page in Internet] ICMR Guidelines for management of type 1 diabetes. [Last Cited on 27th January 2023]. Available from: https://main.icmr.nic.in/sites/default/files/upload_documents/ICMR_Guidelines_for_Management_of_Type_1_Diabetes.pdf

  10. Gianani R, Eisenbarth GS (2005) The stages of type 1A diabetes: 2005. Immunol Rev 204:232–249

    Article  CAS  PubMed  Google Scholar 

  11. Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C et al (2005) Effects of oral insulin in relatives of patients with type 1 diabetes: the diabetes prevention trial–type 1. Diabetes Care 28(5):1068–1076

    Article  CAS  PubMed  Google Scholar 

  12. Skyler JS (2007) Prediction and prevention of type 1 diabetes: progress, problems, and prospects. Clin Pharmacol Ther 81:768–771

    Article  CAS  PubMed  Google Scholar 

  13. Martin S, Pawlowski B, Greulich B, Ziegler AG, Mandrup-Poulsen T, Mahon J (1992) Natural course of remission in IDDM during 1st yr after diagnosis. Diabetes Care 15(1):66–74

    Article  CAS  PubMed  Google Scholar 

  14. Pasquali L, Fan Y, Trucco M, Ringquist S (2006) Rehabilitation of adaptive immunity and regeneration of beta cells. Trends Biotechnol 24(11):516–522

    Article  CAS  PubMed  Google Scholar 

  15. Masharani UB, Becker J (2010) Teplizumab therapy for type 1 diabetes. Expert Opin Biol Ther 10(3):459–465

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Subramanian S, Baidal D (2021) The management of type 1 diabetes. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279114/23

  17. Eisenbarth GS, Srikanta S, Jackson R, Rabinowe S, Dolinar R, Aoki T et al (1985) Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Res 2(6):271–276

    CAS  PubMed  Google Scholar 

  18. Bougnères PF, Landais P, Boisson C, Carel JC, Frament N, Boitard C et al (1990) Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes 39(10):1264–1272

    Article  PubMed  Google Scholar 

  19. Parving HH, Tarnow L, Nielsen FS, Rossing P, Mandrup-Poulsen T, Osterby R et al (1999) Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study. Diabetes Care 22(3):478–83

  20. Silverstein J, Maclaren N, Riley W, Spillar R, Radjenovic D, Johnson S (1988) Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 319(10):599–604

    Article  CAS  PubMed  Google Scholar 

  21. Chatenoud L (2010) Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies? Nat Rev Endocrinol 6(3):149–157

    Article  CAS  Google Scholar 

  22. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R et al (2009) Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 361(22):2143–52

  23. Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R et al (2011) Type 1 Diabetes TrialNet Abatacept Study Group. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 378(9789):412–9

  24. Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE et al (2013) T1DAL Study Team. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol 1(4):284–94

  25. Pescovitz MD, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, Goland R et al (2014) Type 1 Diabetes TrialNet Anti-CD20 Study Group. B-lymphocyte depletion with rituximab and β-cell function: two-year results. Diabetes Care 37(2):453–9

  26. Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R et al (2013) Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 381(9881):1905–1915

    Article  CAS  PubMed  Google Scholar 

  27. Agardh CD, Lynch KF, Palmér M, Link K, Lernmark A (2009) GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes. Diabetologia 52(7):1363–1368

    Article  CAS  PubMed  Google Scholar 

  28. Mastrandrea L, Yu J, Behrens T, Buchlis J, Albini C, Fourtner S et al (2009) Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 32(7):1244–1249

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Roep BO, Solvason N, Gottlieb PA, Abreu JRF, Harrison LC, Eisenbarth GS et al (2013) BHT-3021 Investigators; Steinman L. Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8+ T cells in type 1 diabetes. Sci Transl Med 5(191):191ra82

  30. Chatenoud L, Primo J, Bach JF (1997) CD3 antibody-induced dominant self-tolerance in overtly diabetic NOD mice. J Immunol 158(6):2947–2954

    Article  CAS  PubMed  Google Scholar 

  31. Nadeem A, Ashraf MR, Javed M, Hussain T, Tariq MS, Babar ME (2018) Review - microRNAs: a new paradigm towards mechanistic insight of diseases. Pak J Pharm Sci 31(5):2017–2026

    CAS  PubMed  Google Scholar 

  32. Drugbank [Home page in Internet] Teclizumab. [Last cited on 27th January 2023] Available from: https://go.drugbank.com/drugs/DB06273

  33. Cosimi AB, Colvin RB, Burton RC, Rubin RH, Goldstein G, Kung PC et al (1981) Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med 305(6):308–314

    Article  CAS  PubMed  Google Scholar 

  34. Hooks MA, Wade CS, Millikan WJ Jr (1991) Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and 37. clinical use in transplantation. Pharmacotherapy 11(1):26–37

  35. Chatenoud L, Baudrihaye MF, Chkoff N, Kreis H, Goldstein G, Bach JF (1986) Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J Immunol 137(3):830–838

    Article  CAS  PubMed  Google Scholar 

  36. Chatenoud L, Ferran C, Legendre C, Thouard I, Merite S, Reuter A et al (1990) In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 49(4):697–702

  37. Smith KG, Austyn JM, Hariri G, Beverley PC, Morris PJ (1986) T cell activation by anti-T3 antibodies: comparison of IgG1 and IgG2b switch variants and direct evidence for accessory function of macrophage Fc receptors. Eur J Immunol 16(5):478–486

    Article  CAS  PubMed  Google Scholar 

  38. Parren PW, Warmerdam PA, Boeije LC, Capel PJ, van de Winkel JG, Aarden LA (1992) Characterization of IgG FcR-mediated proliferation of human T cells induced by mouse and human anti-CD3 monoclonal antibodies. Identification of a functional polymorphism to human IgG2 anti-CD3. J Immunol 148(3):695–701

  39. Vallhonrat H, Williams WW, Cosimi AB, Tolkoff-Rubin N, Ginns LC, Wain JC et al (1999) In vivo generation of C4d, Bb, iC3b, and SC5b-9 after OKT3 administration in kidney and lung transplant recipients. Transplantation 67(2):253–258

    Article  CAS  PubMed  Google Scholar 

  40. Hirsch R, Bluestone JA, DeNenno L, Gress RE (1990) Anti-CD3 F(ab’)2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation 49(6):1117–1123

    Article  CAS  PubMed  Google Scholar 

  41. Cole MS, Stellrecht KE, Shi JD, Homola M, Hsu DH, Anasetti C et al (1999) HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. Transplantation 68(4):563–571

    Article  CAS  PubMed  Google Scholar 

  42. Xu D, Alegre ML, Varga SS, Rothermel AL, Collins AM, Pulito VL et al (2000) In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol 200(1):16–26

    Article  CAS  PubMed  Google Scholar 

  43. Vudattu NK, Herold KC (2014) Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development. Expert Opin Biol Ther 14(3):377–385

    Article  CAS  PubMed  Google Scholar 

  44. Daifotis AG, Koenig S, Chatenoud L, Herold KC (2013) Anti-CD3 clinical trials in type 1 diabetes mellitus. Clin Immunol 149(3):268–278

    Article  CAS  PubMed  Google Scholar 

  45. Hagopian W, Ferry RJ Jr, Sherry N, Carlin D, Bonvini E, Johnson S et al (2013) Protégé Trial Investigators. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes 62(11):3901–8

  46. U.S Food and Drug Administration [Home page in Internet] FDA approved drug products: TZIELD (teplizumab-mzwv) injection for intravenous use. [Last Cited on 27th January 2023] Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-can-delay-onset-type-1-diabetes

  47. Sims EK, Bundy BN, Stier K, Serti E, Lim N, Long SA et al (2021) Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med 13(583):eabc8980

  48. Smigoc Schweiger D (2022) Recent advances in immune-based therapies for type 1 diabetes. Horm Res Paediatr

  49. Dayan CM, Korah M, Tatovic D, Bundy BN, Herold KC (2019) Changing the landscape for type 1 diabetes: the first step to prevention. Lancet 394(10205):1286–1296

    Article  CAS  PubMed  Google Scholar 

  50. Felton JL, Conway H, Bonami RH (2021) B Quiet: autoantigen-specific strategies to silence raucous B lymphocytes and halt cross-talk with t cells in type 1 diabetes. Biomedicines 9(1):42

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Gaglia J, Kissler S (2019) Anti-CD3 antibody for the prevention of type 1 diabetes: a story of perseverance. Biochemistry 58(40):4107–4111

    Article  CAS  PubMed  Google Scholar 

  52. Kaplon H, Reichert JM (2021) Antibodies to watch in 2021. MAbs 13(1):1860476

    Article  PubMed  PubMed Central  Google Scholar 

  53. Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ et al (2019) An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 381(7):603–613

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Linsley PS, Long SA (2019) Enforcing the checkpoints: harnessing T-cell exhaustion for therapy of T1D. Curr Opin Endocrinol Diabetes Obes 26(4):213–218

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Tooley JE, Vudattu N, Choi J, Cotsapas C, Devine L, Raddassi K et al (2016) Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes. Eur J Immunol 46(1):230–241

    Article  CAS  PubMed  Google Scholar 

  56. Chatenoud L, Primo J, Bach JF (1997) CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 158(6):2947–2954

    Article  CAS  PubMed  Google Scholar 

  57. You S, Leforban B, Garcia C, Bach JF, Bluestone JA, Chatenoud L (2007) Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A 104(15):6335–6340

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. You S, Slehoffer G, Barriot S, Bach JF, Chatenoud L (2004) Unique role of CD4+CD62L+ regulatory T cells in the control of autoimmune diabetes in T cell receptor transgenic mice. Proc Natl Acad Sci USA 101(Suppl 2):14580–5

  59. Belghith M, Bluestone JA, Barriot S, Mégret J, Bach JF, Chatenoud L (2003) TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 9(9):1202–1208

    Article  CAS  PubMed  Google Scholar 

  60. Penaranda C, Tang Q, Bluestone JA (2011) Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J Immunol 187(4):2015–2022

    Article  CAS  PubMed  Google Scholar 

  61. Esplugues E, Huber S, Gagliani N, Hauser AE, Town T, Wan YY et al (2011) Control of TH17 cells occurs in the small intestine. Nature 475(7357):514–518

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Waldron-Lynch F, Henegariu O, Deng S, Preston-Hurlburt P, Tooley J, Flavell R et al (2012) Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients. Sci Transl Med 4(118):118ra12

  63. Nourelden AZ, Elshanbary AA, El-Sherif L, Benmelouka AY, Rohim HI, Helmy SK et al (2021) Safety and efficacy of teplizumab for treatment of type one diabetes mellitus: a systematic review and meta-analysis. Endocr Metab Immune Disord Drug Targets 21(10):1895–1904

    Article  CAS  PubMed  Google Scholar 

  64. Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA (2013) AbATE Study Team. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 62(11):3766–74

  65. Skelley JW, Elmore LK, Kyle JA (2012) Teplizumab for treatment of type 1 diabetes mellitus. Ann Pharmacother 46(10):1405–1412

    Article  PubMed  Google Scholar 

  66. Mital S, Nguyen HV (2020) Cost effectiveness of teplizumab for prevention of type 1 diabetes among different target patient groups. Pharmacoeconomics 38(12):1359–1372

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, Kalpana Chawla Government Medical College, Karnal, Haryana, India

    Saurav Misra

  2. Department of Pharmacology, AIIMS Bhopal, Bhopal, Madhya Pradesh, India

    Ajay Kumar Shukla

Authors
  1. Saurav Misra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ajay Kumar Shukla
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Concept or design of the article: Dr Saurav Misra, Dr Ajay Kumar Shukla. Drafted the article or revised: Dr Saurav Misra. Approved the version to be published: Dr Ajay Kumar Shukla.

Corresponding author

Correspondence to Saurav Misra.

Ethics declarations

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Misra, S., Shukla, A.K. Teplizumab: type 1 diabetes mellitus preventable?. Eur J Clin Pharmacol 79, 609–616 (2023). https://doi.org/10.1007/s00228-023-03474-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-023-03474-8

Keywords

Search

Navigation